Antithyroid Drug Use in Pregnancy
Methimazole (MMI) is not the preferred antithyroid drug during the first trimester of pregnancy due to teratogenic risk (MMI embryopathy). [1] During the second and third trimesters, methimazole can be used when clinically indicated, including in patients who require ongoing antithyroid therapy. [1]
Guideline-Based Recommendation for Timing
Propylthiouracil (PTU) is recommended during the first trimester to reduce fetal risk associated with methimazole exposure. [1] Switching from methimazole to PTU when planning pregnancy and during early pregnancy is recommended by major endocrine guidance for Graves’ hyperthyroidism. [2] After the first trimester, switching back to methimazole is recommended to reduce maternal hepatotoxicity associated with prolonged PTU exposure. [1]
Safety Considerations Specific to Methimazole
Methimazole exposure in the first trimester is associated with congenital malformations in drug labeling and in guideline discussions of MMI embryopathy. [3] Maternal undertreatment of hyperthyroidism is associated with adverse pregnancy outcomes, so effective maternal thyroid hormone control is a key safety priority. [1]
Treatment Selection Algorithm for Graves’ Hyperthyroidism in Pregnancy
- First trimester (early pregnancy): PTU is selected over methimazole when antithyroid drug therapy is needed. [1]
- Second and third trimesters: methimazole is an acceptable option when ongoing antithyroid drug therapy is required. [1]
- Patients already taking methimazole who become pregnant: switching to PTU as early as possible in the first trimester is recommended. [1]
- Patients already switched off methimazole for early pregnancy: methimazole can be resumed after the first trimester based on guidance. [1]
Dosing and Monitoring Principles During Pregnancy
Antithyroid drug dosing should be adjusted to maintain maternal free thyroxine (FT4) in the appropriate range for pregnancy to avoid fetal hypothyroidism from maternal overtreatment. [1] Close monitoring of maternal thyroid function is required during pregnancy while using antithyroid drugs. [1]
Common Pitfalls
Methimazole use during the first trimester is a common preventable exposure that can be avoided by early switching to PTU when antithyroid therapy is required. [1] Overtreatment with antithyroid drugs can cause maternal hypothyroidism and fetal hypothyroidism, so dosing targets must be followed. [1]
Practical Clinical Bottom Line for This Scenario
Methimazole is not considered the preferred antithyroid drug for the first trimester of pregnancy. [1] If methimazole is being used in early pregnancy, guideline-consistent management involves switching to PTU in the first trimester and using methimazole again after the first trimester when appropriate. [1]
Maternal-Fetal Risk Balancing With Effective Therapy
Avoidance of excessive fetal thyroid hormone exposure is achieved through antithyroid drug therapy that controls maternal hyperthyroidism. [2]
Contraception Planning and Medication Transition
Definitive pregnancy planning and early transition planning from methimazole to PTU when pregnancy is expected are recommended to minimize first-trimester methimazole exposure. [2]